{'fraction_non_alphanumeric': 0.041726618705035974, 'fraction_numerical': 0.06330935251798561, 'mean_word_length': 5.27027027027027, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Phase I evaluation of ICRF‐187 (NSC‐169780) in patients with advanced malignancy

ICRF‐187 (NSC‐169780), the (+) enantiomer of the racemic antineoplastic agent ICRF‐159 (NSC‐129943), was administered intravenously for five days every three weeks to 18 patients in a phase I study. Leukopenia was the dose‐limiting toxicity. Mild reversible elevations in SGOT and bilirubin were common. Other toxicities were mild and infrequent. Recommended doses of ICRF‐187 for phase II studies are 800 mg/m2for heavily pretreated patients and 1250 mg/m2for patients with little or no prior therapy. A daily five day intravenous schedule should be used. Other potential clinical uses of ICRF‐187 are discussed.